167 related articles for article (PubMed ID: 28656083)
1.
Kazemi-Lomedasht F; Pooshang-Bagheri K; Habibi-Anbouhi M; Hajizadeh-Safar E; Shahbazzadeh D; Mirzahosseini H; Behdani M
Iran J Basic Med Sci; 2017 May; 20(5):489-496. PubMed ID: 28656083
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of angiogenesis in human endothelial cell using VEGF specific nanobody.
Kazemi-Lomedasht F; Behdani M; Bagheri KP; Habibi-Anbouhi M; Abolhassani M; Arezumand R; Shahbazzadeh D; Mirzahoseini H
Mol Immunol; 2015 May; 65(1):58-67. PubMed ID: 25645505
[TBL] [Abstract][Full Text] [Related]
3. Oligoclonal selection of nanobodies targeting vascular endothelial growth factor.
Ahadi M; Ghasemian H; Behdani M; Kazemi-Lomedasht F
J Immunotoxicol; 2019 Dec; 16(1):34-42. PubMed ID: 30409071
[TBL] [Abstract][Full Text] [Related]
4. Production and Characterization of Novel Camel Single Domain Antibody Targeting Mouse Vascular Endothelial Growth Factor.
Kazemi-Lomedasht F; Behdani M; Habibi-Anbouhi M; Shahbazzadeh D
Monoclon Antib Immunodiagn Immunother; 2016 Jun; 35(3):167-71. PubMed ID: 27167350
[TBL] [Abstract][Full Text] [Related]
5. Development of a mono-specific anti-VEGF bivalent nanobody with extended plasma half-life for treatment of pathologic neovascularization.
Sadeghi A; Behdani M; Muyldermans S; Habibi-Anbouhi M; Kazemi-Lomedasht F
Drug Test Anal; 2020 Jan; 12(1):92-100. PubMed ID: 31476257
[TBL] [Abstract][Full Text] [Related]
6. Investigation of the therapeutic potential of recombinant bispecific bivalent anti-PD-L1/VEGF nanobody in inhibition of angiogenesis.
Hassanzadeh Eskafi A; Oghalaei A; Mahboudi F; Ghaderi H; Behdani M; Shoari A; Kazemi-Lomedasht F
Immunopharmacol Immunotoxicol; 2023 Apr; 45(2):197-202. PubMed ID: 36193665
[TBL] [Abstract][Full Text] [Related]
7. A nanobody directed to a functional epitope on VEGF, as a novel strategy for cancer treatment.
Farajpour Z; Rahbarizadeh F; Kazemi B; Ahmadvand D
Biochem Biophys Res Commun; 2014 Mar; 446(1):132-6. PubMed ID: 24569074
[TBL] [Abstract][Full Text] [Related]
8.
Mohseni N; Roshan R; Naderi S; Behdani M; Kazemi-Lomedasht F
Iran J Basic Med Sci; 2020 Oct; 23(10):1335-1339. PubMed ID: 33149867
[TBL] [Abstract][Full Text] [Related]
9. Identification and characterization of a novel nanobody against human placental growth factor to modulate angiogenesis.
Arezumand R; Mahdian R; Zeinali S; Hassanzadeh-Ghassabeh G; Mansouri K; Khanahmad H; Namvar-Asl N; Rahimi H; Behdani M; Cohan RA; Eavazalipour M; Ramazani A; Muyldermans S
Mol Immunol; 2016 Oct; 78():183-192. PubMed ID: 27648860
[TBL] [Abstract][Full Text] [Related]
10. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
[TBL] [Abstract][Full Text] [Related]
11. Inhibiting angiogenesis with human single-chain variable fragment antibody targeting VEGF.
Hosseini H; Rajabibazl M; Ebrahimizadeh W; Dehbidi GR
Microvasc Res; 2015 Jan; 97():13-8. PubMed ID: 25250517
[TBL] [Abstract][Full Text] [Related]
12. Production of Novel VHH Nanobody Inhibiting Angiogenesis by Targeting Binding Site of VEGF.
Ebrahimizadeh W; Mousavi Gargari SL; Javidan Z; Rajabibazl M
Appl Biochem Biotechnol; 2015 Aug; 176(7):1985-95. PubMed ID: 26054617
[TBL] [Abstract][Full Text] [Related]
13. Targeting Neuropilin-1 with Nanobodies Reduces Colorectal Carcinoma Development.
De Vlaeminck Y; Bonelli S; Awad RM; Dewilde M; Rizzolio S; Lecocq Q; Bolli E; Santos AR; Laoui D; Schoonooghe S; Tamagnone L; Goyvaerts C; Mazzone M; Breckpot K; Van Ginderachter JA
Cancers (Basel); 2020 Nov; 12(12):. PubMed ID: 33266104
[TBL] [Abstract][Full Text] [Related]
14. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
Bae DG; Kim TD; Li G; Yoon WH; Chae CB
Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
[TBL] [Abstract][Full Text] [Related]
15. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
[TBL] [Abstract][Full Text] [Related]
16. Characterization and applications of Nanobodies against human procalcitonin selected from a novel naïve Nanobody phage display library.
Yan J; Wang P; Zhu M; Li G; Romão E; Xiong S; Wan Y
J Nanobiotechnology; 2015 May; 13():33. PubMed ID: 25944262
[TBL] [Abstract][Full Text] [Related]
17. Nanobodies As Novel Agents for Targeting Angiogenesis in Solid Cancers.
Arezumand R; Alibakhshi A; Ranjbari J; Ramazani A; Muyldermans S
Front Immunol; 2017; 8():1746. PubMed ID: 29276515
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor.
Lin P; Sankar S; Shan S; Dewhirst MW; Polverini PJ; Quinn TQ; Peters KG
Cell Growth Differ; 1998 Jan; 9(1):49-58. PubMed ID: 9438388
[TBL] [Abstract][Full Text] [Related]
19. Screening and identification of an anti-PD-1 nanobody with antitumor activity.
Zhang Y; Yang S; Jiang D; Li Y; Ma S; Wang L; Li G; Wang H; Zhang A; Xu G
Biosci Rep; 2022 Dec; 43(1):. PubMed ID: 36475449
[TBL] [Abstract][Full Text] [Related]
20. IKKβ targeting reduces KRAS-induced lung cancer angiogenesis in vitro and in vivo: A potential anti-angiogenic therapeutic target.
Carneiro-Lobo TC; Scalabrini LC; Magalhães LDS; Cardeal LB; Rodrigues FS; Dos Santos EO; Baldwin AS; Levantini E; Giordano RJ; Bassères DS
Lung Cancer; 2019 Apr; 130():169-178. PubMed ID: 30885340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
